HWAM
DAWN

Hennion & Walsh Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Hennion & Walsh Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-367,134
Closed -$7.87M – 969
2026
Q1 		$7.87M Buy
367,134
+53,679
+17% +$756K 0.26% 77
2025
Q4 		$2.92M Buy
313,455
+218,383
+230% +$1.82M 0.1% 261
2025
Q3 		$670K Sell
95,072
-1,749
-2% -$12K 0.02% 620
2025
Q2 		$629K Sell
96,821
-41,147
-30% -$283K 0.03% 604
2025
Q1 		$1.09M Buy
137,968
+16,801
+14% +$181K 0.05% 454
2024
Q4 		$1.54M Buy
121,167
+57,601
+91% +$802K 0.07% 353
2024
Q3 		$885K Sell
63,566
-793
-1% -$11.3K 0.04% 474
2024
Q2 		$887K Buy
64,359
+5,070
+9% +$74.2K 0.05% 453
2024
Q1 		$979K Buy
59,289
+1,445
+2% +$21.6K 0.05% 423
2023
Q4 		$845K Buy
57,844
+4,041
+8% +$49K 0.05% 445
2023
Q3 		$660K Buy
53,803
+25,414
+90% +$332K 0.04% 451
2023
Q2 		$339K Buy
+28,389
New +$371K 0.02% 616

Other funds holding DAWN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Hennion & Walsh Asset Management's DAWN Position: Q2 2026 in Review

Hennion & Walsh Asset Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 367,134 shares — an estimated $7.87M sold.

Hennion & Walsh Asset Management first reported a position in DAWN in Q2 2023 and held it in 12 quarters. The position peaked at $7.87M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

  • Hennion & Walsh Asset Management reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 367,134 Day One Biopharmaceuticals shares in Q2 2026, an estimated $7.87M.
  • Hennion & Walsh Asset Management first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 12 quarters.
  • Hennion & Walsh Asset Management's Day One Biopharmaceuticals position peaked at $7.87M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.